title: Renal transplantation in recipients over the age of 60: the impact of donor age.
abstract: BACKGROUND
  Kidneys from older donors exhibit a series of changes characterized by glomerular, vascular, and tubular senescence. These changes may be aggravated by atherosclerosis, hypertension, or diabetes, which are highly prevalent in older individuals.
  
  
  METHODS
  We analyzed the outcome after transplantation in 230 recipients over the age of 60, who received transplants between February 1990 and December 1996. We assessed the 1- and 5-year patient and graft survival, the quality of renal function, tacrolimus levels, the incidence of rejection, and the incidence of delayed graft function, and compared the outcomes in recipients of kidneys from donors over the age of 60 (group 1, n = 40) with those in recipients of kidneys from donors under the age of 60 (group 2, n = 190). There were no differences between the two groups in terms of recipient sex, race, age, and cold ischemia time. Immunosuppression was with tacrolimus and steroids in 61% of cases; in the remainder of the patients, a third agent, either azathioprine, cyclophosphamide (for 1 week), or mycophenolate mofetil was administered as well. The median follow-up was 31.5 months (range: 1-86).
  
  
  RESULTS
  In recipients over the age of 60 receiving tacrolimus-based immunosuppression, overall patient survival at 1 and 5 years was 90% and 76%, and was not significantly compromised in recipients receiving a kidney from a donor over the age of 60. The overall 1-and 5-year actuarial graft survival was 84% and 64%; in recipients from donors over the age of 60, it was 73% and 52%, whereas in recipients of kidneys from donors under the age of 60, it was 87% and 66% (P<0.05). Most of the effect on graft survival was seen by 1 year. The mean serum creatinine was 2.6+/-2.7 mg/dl, without any difference between the two groups. Although the incidence of delayed graft function was higher in recipients of kidneys from donors over the age of 60, this difference did not reach statistical significance.
  
  
  CONCLUSIONS
  Although the overall outcomes of transplantation in older recipients remain reasonable, the inferior outcomes with older donor kidneys call into question proposals to utilize older donor kidneys preferentially in older recipients.
authors.affiliation: Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pennsylvania 15213, USA.
authors.forename: H
authors.initials: H
authors.lastname: Basar
authors.forename: A
authors.initials: A
authors.lastname: Soran
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: C
authors.initials: C
authors.lastname: Vivas
authors.forename: V P
authors.initials: VP
authors.lastname: Scantlebury
authors.forename: M L
authors.initials: ML
authors.lastname: Jordan
authors.forename: H A
authors.initials: HA
authors.lastname: Gritsch
authors.forename: J
authors.initials: J
authors.lastname: McCauley
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
authors.forename: W
authors.initials: W
authors.lastname: Irish
authors.forename: T R
authors.initials: TR
authors.lastname: Hakala
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology*; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality; D016019:Survival Analysis; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D003404:Creatinine